Skip to content
Search

Latest Stories

Top Stories

Dark magic: Drug companies and the art of deception

Dark magic: Drug companies and the art of deception
Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Magicians know the key to a convincing trick is misdirection.


They instruct you to follow the left hand so that you’ll ignore the right, which is subtly palming a ball or pulling an ace from the sleeve. The art of the illusion hinges on the magician’s ability to divert attention from where the real action is happening. And, therefore, every illusion conceals the truth.

Similarly, the U.S. biopharmaceutical industry has relied on subtle forms of misdirection in response to increased scrutiny from Congress, the Biden administration and health policy experts.

Here are three illusions drug companies have crafted to maintain massive profitability:

Illusion No. 1: A Death-Defying Feat

Drug research and development (R&D) has, for decades, gifted humanity with medical wonders: antibiotics, statins, cancer therapies and HIV/AIDS treatments.

In the 21st century, however, drug innovation has slowed while pharma companies have made exorbitant pricing a key business strategy. Over the past 18 years, biopharma companies have earned an average gross profit margin of 77%. Last year, the five largest pharma firms generated more than $81.9 billion in profits.

To combat runaway drug prices, Congress passed the Inflation Reduction Act last year, allowing the U.S. government to negotiate prices for a limited number of expensive medications starting in 2026.

The pharmaceutical sector immediately filed lawsuits. In public remarks, drug spokespeople have created the illusion that any reduction in drug-industry profits will destroy R&D innovation and harm millions of patients.

The Hidden Truth

Hidden in this illusion are three facts drug companies don’t want Americans to know. Combined, these truths tell a different story about pharmaceutical research and development.

First, an overwhelming percentage of drug prices gets channeled into corporate profits and administrative costs, not R&D. In fact, a report during the height of the pandemic found that 7 in 10 major drug companies spent more on marketing and sales than R&D.

Second, research concludes that price constraints would minimally impact drug discovery. The Congressional Budget Office estimates that reducing the pharmaceutical revenues would result in just one less drug over the next decade and a total of 1% fewer medications over the next 30 years.

The third and most pernicious part of the illusion is getting people to ignore how many Americans are harmed by the unaffordability of life-essential medications. One example is insulin prices, which have tripled over the past decade. As a result, researchers from Yale found 25% of children with type 1 diabetes are given lower doses by their parents than their physicians recommend.

Nearly 1 in 4 Americans on prescription drugs now report difficulty affording their medications. That is the hidden truth. Exorbitant Rx prices hurt and kill far more Americans than the supposed loss of R&D ever would.

Illusion No. 2: The Statue Of Liberty Trick

Once Americans buy into the illusion that exorbitant drug prices are necessary to save lives, pharmaceutical companies move on to the next sleight of hand.

It goes like this: The United States, alone, must shoulder the enormous burden of drug prices.

Right now, Americans pay 2.4 to 3.4 times more for medications than in peer nations.

Much of the disparity in spending dates back to 2003 when Congress passed a law prohibiting the U.S. government from negotiating drug prices. And without any pricing regulations in place, domestic drug companies have pushed the boundaries ever higher. Over the past two years, nearly half of FDA approved medications have debuted above $150,000 with several topping $1 million per patient.

Outside of the United States, excessively high drug prices are a rarity.

Ozempic exemplifies the problem. This diabetes drug helps people lose significant weight while also avoiding heart attacks. A month’s supply of it costs $936 in the United States. In Japan, it sells for $169. It’s just $93 in the UK, $87 in Australia and $83 France.

Each of these countries has instituted drug-pricing controls and caps on drugmaker profits. If our nation adopted the same regulations, we could prescribe Ozempic to every overweight and obese American, and affordably solve the obesity epidemic. But under current retail pricing, doing so would increase drug spending $1.5 trillion per year, raising overall healthcare costs by 25%.

The Hidden Truth

The illusion here is that drug prices in other wealthy nations are non-negotiable.

But of course, that’s not accurate. American drug companies could play hardball with peer countries, refusing to sell their medications unless a more equitable pricing structure can be reached.

But why bother when you can simply stick Americans with the bill?

Illusion No. 3: What’s In Your Pocket?

When it comes to purchasing prescription drugs, there are two prices. There’s the very high retail price drug companies charge and the much-smaller amount insured patients pay when they pick up their medications (the out-of-pocket expense).

Since out-of-pockets are only small fraction of the total drug expense, drug companies would like Americans to concentrate on those dollars. But that requires people to assume the rest of the money—paid by the government or private businesses—is free.

The Hidden Truth

The reality is that workers and taxpayers wind up paying the price for expensive medications in two ways:

1. Workers earn less pay as benefit costs increase. That’s because employers treat wages and healthcare benefits as a single expense. As medical costs soar, raises disappear and salaries stagnate.

2. Taxpayers either pay more or get less. When medical costs rise, the government must either raise taxes or cut programs, including school funding and public safety.

Deception and misdirection can be sources of wonder at magic shows. But illusions in healthcare prove to be disturbing, dangerous and deadly.

Read More

Handcuffs, taxes, law, police, enforcement, tax

ProPublica has obtained the blueprint for the Trump administration’s unprecedented plan to turn over IRS records to Homeland Security in order to speed up the agency’s mass deportation efforts.

Ricardo Tomás for ProPublica

The IRS Is Building a Vast System To Share Millions of Taxpayers’ Data With ICE

The Internal Revenue Service is building a computer program that would give deportation officers unprecedented access to confidential tax data.

ProPublica has obtained a blueprint of the system, which would create an “on demand” process allowing Immigration and Customs Enforcement to obtain the home addresses of people it’s seeking to deport.

Keep ReadingShow less
Defend Democracy Against Bombardments on the Elections Front –A Three-Part Series
low angle photography of beige building

Defend Democracy Against Bombardments on the Elections Front –A Three-Part Series

In Part One of this three-part series, Pat Merloe explored the impact of the political environment, the need for constitutional defense against power-grabbing, and the malign effects of proof of citizenship on voting.

In Part Two, Merloe explored the harmful effects of Executive Orders, the reversal of the Justice Department on voting rights, and the effects of political retribution.

Part Three: Attacks on the Courts, and the Need to Defend Universal and Equal Suffrage

As noted in Parts One and Two of this series, multipoint attacks against trustworthy elections are underway with just 16 months until 2026’s voting and less time before off-year elections this November. Awareness of the attacks – and those fortifying trustworthy processes – is crucial for defending democracy.

Keep ReadingShow less
Bay Area Social Media Post Claims ICE Cannot Enter Library, Fuels Misinformation

South Novato Library, California

Pricila Flores

Bay Area Social Media Post Claims ICE Cannot Enter Library, Fuels Misinformation

Bay Area community advocates are cautioning community members to be wary of what they see, interact with, and post on social media regarding information about the United States Immigration and Customs Enforcement (ICE) and immigration, following a rumor that targeted the Marin County Library.

‘South Novato Library has safe rooms that cannot be accessed by border patrol or ICE without a court order,’ an Instagram story post reads, with photos of a room in the library next to the text alongside the library address. The graphic claims Immigration and Customs Enforcement would not have the right to enter the pictured room without a court-ordered warrant.

Despite the graphic becoming a popular share among the local community of Novato, a Marin County city located just north of San Francisco, the information is false.

Keep ReadingShow less

Angelica Salas’s Journey From Undocumented Immigrant to Community Leader at CHIRLA

Angelica Salas has long been a leading advocate for immigrant rights in Los Angeles. Since becoming Executive Director of the Coalition for Humane Immigrant Rights of Los Angeles (CHIRLA) in 1999, she has transformed the organization into one of the most powerful immigrant-led advocacy groups in the country. Her leadership has redefined what grassroots organizing can look like, mobilizing communities around issues ranging from Deferred Action for Childhood Arrivals (DACA) to voter outreach and legal services.

Salas’s journey into activism is deeply personal. Born in Durango, Mexico, she arrived in the United States at the age of five, undocumented, to reunite with her parents who had migrated for work. Growing up in Pasadena, California, her family lived in the shadows of deportation until they were able to legalize their status. In 2008, Salas became a U.S. citizen, adding a powerful chapter to a story she shares with many of the people CHIRLA serves. Her own experience navigating the U.S. immigration system informs her commitment to building dignity, not dependency, in the immigrant rights movement. After graduating from Occidental College with a degree in history and sociology, Salas joined CHIRLA in 1995 and became its executive director just four years later.

Keep ReadingShow less